Advertisement

The Development of Molecular Vaccines against Malaria Sporozoites

  • W. Ripley Ballou
  • James F. Young
  • Stanley J. Cryz
  • Jerald C. Sadoff

Abstract

The successful development of an efficacious molecular vaccine against malaria has long been a major research goal of the Walter Reed Army Institute of Research, the World Health Organization and major international public health agencies. Although this goal has not yet been achieved, immense progress has been made in the area of sporozoite vaccines since the gene encoding the Plasmodium falciparum circumsporozoite (CS) protein was cloned and sequenced in 1984 (Dame et al., 1984). The basis for a subunit approach to sporozoite immunity was established in the early 1970’s in a series of landmark studies demonstrating that mice, primates, and humans could be protected against sporozoite challenge by immunization with radiation-attenuated sporozoites (Nussenzweig et al. 1969; Clyde et al., 1975; Rieckman et al., 1979). These studies demonstrated that protective immunity was species and stage specific, but since large numbers of sporozoites were required for its induction, it was not feasible to develop live attenuated sporozoite vaccines for general use. Moreover, the mechanism of immunity to irradiated sporozoites is complex, and includes the induction of both humoral and cellular immune responses.

Keywords

Plasmodium Falciparum Circumsporozoite Protein Walter Reed Army Institute Falciparum Sporozoite Sporozoite Challenge 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ballou, W.R., Rothbard, J., Wirtz, R.A., Gordon, D.M., Williams, J.S., Gore, R.W., Schneider, I., Hollingdale, M.R., Beaudoin, R.L., Maloy, W.L., Miller, L.H., Hockmeyer, W.T. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science. 228:996 (1985).PubMedCrossRefGoogle Scholar
  2. Ballou, W.R., Hoffman, S.L., Sherwood, J.A., Hollingdale, M.R., Neva, F.A., Hockmeyer, W.T., Gordon, D.M., Schneider, I., Wirtz, R.A., Young, J.F., Wasserman, G.F., Reeve, P., Diggs, C.L., Chulay, J.D. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. i:1277 (1987).CrossRefGoogle Scholar
  3. Chen, D.H., Tigelarr, R. E., Weinbaum, F.I. Immunity to sporozoite induced malaria infection in mice. I. The effect of immunization of T and B cell deficient mice. J Immunol. 188:1322(1977).Google Scholar
  4. Chulay, J.D., Schneider I., Cosgriff T.M., Hoffman S.L., Ballou, W.R., Quakyi, I.A., Carter, R., Trosper, J.H., Hockmeyer, W.T. Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum. Am J Trop Med Hyg. 35:66, 1986.PubMedGoogle Scholar
  5. Clough, E.R., Audibert, F.M., Barnwell, J.W., Schlesinger, D.H., Arnon, R., Chedid, L.A. Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative. Inf Immun. 48:839, 1985.Google Scholar
  6. Clyde, D.F., McCarthy, V.C., Miller, R.M., Woodward, W.E. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 24:397 (1975).PubMedGoogle Scholar
  7. Dame, J.B., Williams, J.L., McCutchan, T.F., Weber, J.L., Wirtz, R.A., Hockmeyer, W.T., Maloy, W.L., Haynes, J.D., Schneider, I., Roberts, D., Sanders, G.S., Reddy, E.P., Diggs, C.L., Miller, L.H.. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 225:593 (1984).PubMedCrossRefGoogle Scholar
  8. Egan, J.E., Weber, J.L., Ballou, W.R., Hollingdale, M.R., Majarian, W.R., Gordon, D.M., Maloy, W.L., Hoffman, S.L., Wirtz, R.A., Schneider, I., Woollett, G.R., Young, J.F., Hockmeyer, W.T. Efficacy of murine malaria sporozoite vaccines: Implications for human vaccine development. Science. 236:453 (1987).PubMedCrossRefGoogle Scholar
  9. Ferreira, A., Schofield, L.A., Enea, V., Schellekens, H., Meide, P., Collins, W.E., Nussenzweig, R.S., Nussenzweig, V. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma interferon. Science. 232:881, 1986.PubMedCrossRefGoogle Scholar
  10. Good, M.F., Berzofsky, J.A., Maloy, W.L., Hayashi, Y., Fujii, N., Hockmeyer, W.T., Miller, L.H. Genetic control of the immune response in mice to Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J Exp Med. 164:655 (1986).PubMedCrossRefGoogle Scholar
  11. Good, M.F., Maloy, W.L., Lunde, M.N., Margalit, H., Cornette, J.L., Smith, G.L., Moss, B, Miller, L.H., Berzofsky, J.A. Construction of synthetic immunogen: Use of new T-helper epitope on malaria circumsporozoite protein. Science. 235:1059 (1987).PubMedCrossRefGoogle Scholar
  12. Good, M.F., Pombo, D., Quakyi I.A., Riley, E.M., Houghten R.A., Menon, A., Alling, D.W., Berzofsky, J.A., Miller, L.H. Human T cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci, USA. 85:1199, 1988.PubMedCrossRefGoogle Scholar
  13. Guidice, G.D., Engers, H.D., Tounge, C., Biro, S.S., Weiss, N., Verdini, A.S., Pessi, A., Degremont, A.A., Freyvogel, T.A., Lambert, P.H., Tanner, M. Antibodies to the repetitive epitope of Plasmodium falciparum circumsporozoite protein in a rural Tanzanian community: a longitudinal study of 132 children. Am J Trop Med Hyg. 36:203, 1987.Google Scholar
  14. Granden, M., Fridell, E., Kindmark, C.O. Intradermal immunization with reduced doses of human diploid cell strain rabies vaccine: Evaluation of antibody responses by ELISA and mixed hemadsorption test. Scand J Infect Dis. 17:173, 1985.Google Scholar
  15. Herrington, D.A., Clyde, D.F., Losonsky, G., Cortesia, M., Murphy, J.R., Davis, J., Baqar, S., Felix, A.M., Reimer, E.P., Gillessen, D., Nardin, E., Nussenzweig, R.S., Nussenzweig, V., Hollingdale, M., Levine, M.M. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 328:257 (1987).PubMedCrossRefGoogle Scholar
  16. Hoffman, S.L., Oster, C. N., Plowe, C.V., Hollingdale, M.R., Beier, J.C., Chulay, J.D., Wirtz, R.A., Woollett G.R. Mugambi, M. Malaria not prevented by naturally acquired sporozoite antibodies: Implications for vaccine development. Science. 237:639 (1987).PubMedCrossRefGoogle Scholar
  17. Hoffman, S.L., Cannon, L.T., Berzofsky, J.A. Plasmodium falciparum: Sporozoite boosting of immunity due to a T cell epitope on a sporozoite vaccine. Exp Parasitol. 64:64 (1987).PubMedCrossRefGoogle Scholar
  18. Hollingdale, M.R., Nardin E.H., Tharavanij, S., Schwartz, A.L., Nussenzweig R.S. Inhibition of entry of plasmodium falciparum and P. vivax sporozoites into cultured cells: an in vitro assay of protective antibodies. J Immunol. 132:909, 1984.PubMedGoogle Scholar
  19. Levine, M.M., Herrington, D., Murphy, J.R., Morris, J.G., Losonsky, G., Tall, B., Lindberg, A.A., Svenson, S., Baqarq, S., Edwards, M.F., Stocker, B. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest. 79:888, 1987.PubMedCrossRefGoogle Scholar
  20. Lowell, G.H., Ballou, W.R., Smith, L.H., Wirtz, R.A., Zollinger, W.D., Hockmeyer, W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science. 240:800, 1988.PubMedCrossRefGoogle Scholar
  21. Nardin, E.H., Gwadz R.W., Nussenzweig, R.S. Characterization of sporozoite surface antigens by indirect immunofluoresence: detection of stage and species-specific antimalarial antibodies. Bull WHO. 57:211, 1979.PubMedGoogle Scholar
  22. Nussenzweig, R., Vanderberg, J., Most, H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Milit Med. 134:1176 (1969).Google Scholar
  23. Potocnjak, P., Yoshida, N., Nussenzweig, R., Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malaria infection. J Exp Med. 151:1504 (1980).PubMedCrossRefGoogle Scholar
  24. Richards, R.L., Hayre, M.D., Hockmeyer, W.T., Alving, C.R. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Inf Immun. 56:682, 1988.Google Scholar
  25. Rieckmann, K.H., Beaudoin, R.L., Cassells, J.S., Sell, K.W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull WHO. 57:261 (1979).PubMedGoogle Scholar
  26. Rutgers, T., Gordon, D., Gathoye, A.M., Hockmeyer, W.T., DeWilde, M., Rosenberg, M. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of plasmodium falciparum. Biotechnology. (in press).Google Scholar
  27. Sadoff, J.C., Ballou, W.R., Baron, L.S., Majarian, W.R., Brey, R.N., Hockmeyer, W.T., Young, J.F., Cryz, S.J., Ou, J., Lowell, G.H., Chulay, J.D. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 240:336 (1988).PubMedCrossRefGoogle Scholar
  28. Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R., Nussenzweig, V. g Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature. 330:664 (1987).PubMedCrossRefGoogle Scholar
  29. Tagliabue, N.L., Caffarena A., Villa, L., Borasci, D., Cazzola, G., Cavalieri, S. Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Tmmuno. 62:242, 1985.Google Scholar
  30. Vanderberg, J., Nussenzweig, R., Most, H. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Milit Med. 134:1183 (1969).Google Scholar
  31. Verhave, J.P., Strickland, G.T., Jaffe, H.A., Ahmed, A. Studies on the transfer of protective immunity with lymphoid cells from mice immune to malaria sporozoites. J Immunol. 121:1031 (1978).PubMedGoogle Scholar
  32. Weiss, W.R., Sedegah, M., Beaudoin, R.L., Miller, L.H., Good, M.F. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci, USA. 85:573 (1988).PubMedCrossRefGoogle Scholar
  33. Wirtz, R.A., Ballou, W.R., Schneider, I., Chedid, L., Gross, M.J., Young, J.F., Hollingdale, M.R., Diggs, C.L., Hockmeyer, W.T. Plasmodium falciparum: Immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol. 63:166 (1987).PubMedCrossRefGoogle Scholar
  34. Young, J.F., Hockmeyer, W.T., Gross, M.T., Ballou, W.R., Wirtz, R.A., Trosper, J.H., Beaudoin, R.L., Hollingdale, M.R., Miller, L.H., Diggs, C.L., Rosenberg, M. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science. 228:958 (1985).PubMedCrossRefGoogle Scholar
  35. Zavala, F., Cochrane, A.H., Nardin, E.H., Nussenzweig, R.S., Nussenzweig, V. Circumsporozoite proteins of malaria parasites contain a single immuno-dominant region with two or more identical epitopes. J Exp Med. 157:1947 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • W. Ripley Ballou
    • 1
  • James F. Young
    • 2
  • Stanley J. Cryz
    • 3
  • Jerald C. Sadoff
    • 4
  1. 1.Departments of ImmunologyWalter Reed Army Institute of ResearchUSA
  2. 2.Molecular GeneticsSmith Kline & French LaboratoriesKing of PrussiaUSA
  3. 3.Swiss Serum and Vaccine InstituteBerneSwitzerland
  4. 4.Bacterial DiseasesWalter Reed Army Institute of ResearchUSA

Personalised recommendations